Bionest

AI Aiding Earlier, More Accurate Cancer Screening

Recent research clearly illustrates the potential that artificial intelligence (AI) and deep learning systems offer for improving the detection and diagnosis of cancer, whether from radiological images or tissue analysis. While further clinical validation of such systems is needed before they can be reliably deployed in medical practice, they are expected to benefit patient care...

Bionest

Real World Evidence Replacing Some Clinical Trials?

Pharmaceutical companies have long used real-world data on drug performance to help justify their pricing decisions to payers. But now such real-world evidence (RWE), gathered from electronic medical records (EMRs), national patient registries and other patient databases, is increasingly being looked at as a way to make the case for new supplemental approvals and label...

Bionest

News from ASCO: Part 2

In this post, we continue our report on some of the precision medicine approaches and initiatives we noted at ASCO.   Neoantigens Revitalizing Cancer Vaccine Efforts   Early efforts to create cancer vaccines aimed at increasing the immune system’s exposure to tumors, but the effectiveness of first-generation vaccines created by Dendreon and others was limited....

Bionest

News from ASCO: Part 1 

As we previously wrote, ASCO’s focus this year was on driving the benefits of precision medicine approaches in oncology to more patients. This was reflected in several ways in the news coming out of the conference, including:   Progress Against Important, Difficult-to-Target Biomarkers   The ASCO news was particularly good this year for patients with...

Bionest

Building a Better Market for Biologics: The US vs. Europe

The advent of generics has dramatically impacted the cost of small molecule drugs following the expiry of the patent protection for the originator therapeutics, with the cost of a small molecule generic often as little as 10% of that of the originator drug. This price difference results from several factors, including lower R&D costs, fewer...